Agenus Inc.
| NASDAQ: AGEN | Healthcare / Biotechnology / USA |
| 0.7823 | -0.0168 | -2.10% | Vol 16.55M | 1Y Perf -68.79% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 0.7784 | ASK | 0.8000 | ||
| Open | 0.8100 | Previous Close | 0.7991 | ||
| Pre-Market | - | After-Market | 0.80 | ||
| - - | 0.02 2.26% |
| Target Price | 6.83 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 773.07 | Finscreener Ranking | ★★ 46.15 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ☆ 29.69 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★+ 40.26 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.88 | Earnings Rating | Buy | |
| Market Cap | 298.44M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.20 | |
| Beta | 1.33 |
Today's Price Range 0.77410.8150 | 52W Range 0.61343.07 | 5 Year PE Ratio Range -2.40-3.10 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.67% | ||
| 1 Month | -4.62% | ||
| 3 Months | -37.91% | ||
| 6 Months | -58.39% | ||
| 1 Year | -68.79% | ||
| 3 Years | -76.00% | ||
| 5 Years | -70.25% | ||
| 10 Years | -69.68% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 45.46 | |||
ROE last 12 Months | -2 978.48 | |||
ROA (5Y Avg) | -17.74 | |||
ROA last 12 Months | -56.13 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -210.43 | |||
Return on invested Capital Q | -40.04 | |||
Return on invested Capital Y | -51.79 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 13.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.90 | ||||
| 218.61 | ||||
| 10.37 | ||||
| 50.00 | ||||
| -4.30 | ||||
| -0.56 | ||||
| -14.29 | ||||
| -0.07 | ||||
| 592.49M | ||||
| Forward PE | -1.73 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 1.50 | ||||
| 0.95 | ||||
| 23.47 | ||||
| -2.70 | ||||
| Leverage Ratio | -381.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -303.10 | ||||
| -181.40 | ||||
| -173.90 | ||||
| -267.50 | ||||
| 0.57 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 69.64M | ||||
| 0.23 | ||||
| 29.17 | ||||
| 47.57 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.19 | -0.16 | 15.79 |
| Q02 2023 | -0.20 | -0.20 | 0.00 |
| Q01 2023 | -0.21 | -0.22 | -4.76 |
| Q04 2022 | -0.22 | -0.24 | -9.09 |
| Q03 2022 | -0.18 | -0.19 | -5.56 |
| Q02 2022 | -0.23 | -0.17 | 26.09 |
| Q01 2022 | -0.29 | -0.19 | 34.48 |
| Q04 2021 | -0.16 | -0.26 | -62.50 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.06 | 64.71 | Positive |
| 12/2023 FY | -0.63 | 18.18 | Positive |
| 3/2024 QR | -0.15 | 11.76 | Positive |
| 12/2024 FY | -0.45 | 35.71 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.19 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 16.55M |
| Shares Outstanding | 381.50K |
| Shares Float | 363.18M |
| Trades Count | 26.59K |
| Dollar Volume | 13.13M |
| Avg. Volume | 7.86M |
| Avg. Weekly Volume | 9.38M |
| Avg. Monthly Volume | 8.46M |
| Avg. Quarterly Volume | 5.72M |
Agenus Inc. (NASDAQ: AGEN) stock closed at 0.7823 per share at the end of the most recent trading day (a -2.1% change compared to the prior day closing price) with a volume of 16.55M shares and market capitalization of 298.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 328 people. Agenus Inc. CEO is Garo H Armen.
The one-year performance of Agenus Inc. stock is -68.79%, while year-to-date (YTD) performance is -67.4%. AGEN stock has a five-year performance of -70.25%. Its 52-week range is between 0.6134 and 3.0696, which gives AGEN stock a 52-week price range ratio of 6.88%
Agenus Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 218.61, a price-to-sale (PS) ratio of 10.37, a price to cashflow ratio of 50.00, a PEG ratio of -, a ROA of -56.13%, a ROC of -210.43% and a ROE of -2 978.48%. The company’s profit margin is 0.57%, its EBITDA margin is -173.90%, and its revenue ttm is $69.64 Million , which makes it $0.23 revenue per share.
Of the last four earnings reports from Agenus Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Agenus Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Agenus Inc. is Strong Buy (1), with a target price of $6.83, which is +773.07% compared to the current price. The earnings rating for Agenus Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Agenus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Agenus Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.81, ATR14 : 0.08, CCI20 : 94.95, Chaikin Money Flow : -0.24, MACD : -0.03, Money Flow Index : 68.43, ROC : 14.16, RSI : 51.31, STOCH (14,3) : 74.79, STOCH RSI : 0.81, UO : 53.61, Williams %R : -25.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Agenus Inc. in the last 12-months were: Wiinberg Ulf (Buy at a value of $19 000)
Agenus Inc.
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.
CEO: Garo H Armen
Telephone: +1 781 674-4400
Address: 3 Forbes Road, Lexington 02421-7305, MA, US
Number of employees: 328
TipRanks News for AGEN
Tue, 07 Nov 2023 17:31 GMT Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)
- TipRanks. All rights reserved.Tue, 08 Aug 2023 14:45 GMT Agenus (AGEN) Gets a Buy from H.C. Wainwright
- TipRanks. All rights reserved.Wed, 05 Jul 2023 12:05 GMT Agenus (AGEN) Receives a Buy from Jefferies
- TipRanks. All rights reserved.Mon, 03 Jul 2023 10:30 GMT Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), CytomX Therapeutics (CTMX) and Bausch + Lomb Corporation (BLCO)
- TipRanks. All rights reserved.
